Rivipansel: In August 2019, Pfizer reported disappointing results from the Phase 3 RESET trial (NCT02187003) after it failed to meet the primary endpoint of the study. Following termination of Pfizer’s license agreement for rivipansel in April 2020, we committed to determine what, if any, next steps to take in vaso-occlusive sickle cell crisis.
